GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: Canada stopped being a problem at week 61 — 19 comments in the full submission. View in context.
202
c/glp1canada·submitted 2 years ago by u/zaid_grimaldi

small win: Canada stopped being a problem at week 61

Discussionbranch of 7 comments

Right, the special authorization question again, but with numbers this time. I have 5 data points over 18 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I…

Read the full submission and all 19 comments →

This branch

7 comments, started 2 years ago
u/anya_rautio0 points·2 years ago

This is correct. Name your province.

replysharereportpermalink
u/diego_almeida1 point·2 years ago

Week 8 for me and the honest summary is: 39kg down, injection-site soreness manageable, and I have thought about food maybe four times today.

replysharereportpermalink
u/a1c_arcT2D1 point·2 years ago

formulary is the cross-province difference

replysharereportpermalink
u/zaid_grimaldiOP1 point·2 years ago

Week 45 for me and the honest summary is: 24kg down, fatigue manageable, and I have thought about food maybe four times today.

replysharereportpermalink
u/draw_up_dizzy1 point·2 years ago

formulary is the cross-province difference

replysharereportpermalink
u/neha_erdogan1 point·2 years ago

provincial formularies differ sharply

replysharereportpermalink
u/anders_karlsen1 point·2 years ago

This is correct. Name your province.

replysharereportpermalink

← back to the whole thread

About c/glp1canada

Canadian access: provincial formulary differences, private plan coverage, the special-authorisation process, cross-border pricing arbitrage and why the Ontario answer is not the Alberta answer.

17kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1canada rules
  1. Name your province. Coverage is provincial.
  2. Private plan details: redact your group number.
  3. No cross-border purchasing instructions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.